William C. Manning

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

Anne-Marie O'Farrell, Tinya J. Abrams, Helene A. Yuen et al. · Blood · 2003 · 857 citations · Full text

Medicine, Oncology, Pharmacology +11

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease

Walter Fiedler, Hubert Serve, Hartmut Döhner et al. · Blood · 2005 · 492 citations

Medicine, Oncology, Pharmacology +13

Rapid, deep and precise profiling of the plasma proteome with multi-nanoparticle protein corona

John E. Blume, William C. Manning, Gregory Troiano et al. · Nature Communications · 2020 · 454 citations · Full text

Life Sciences, Biochemistry, Biomedical Sciences +17

An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.

A O’Farrell, James M. Foran, Walter Fiedler et al. · PubMed · 2003 · 311 citations

Medicine, Pharmacokinetics, Pharmacology +17

Genomic organization and transcriptional regulation of the RANTES chemokine gene.

Peter J. Nelson, H T Kim, William C. Manning et al. · The Journal of Immunology · 1993 · 265 citations · Full text

Life Sciences, Immunology, Molecular Genetics +16